Taysha Gene Therapies, Inc.
TSHA
$3.00
$0.134.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 78.60% | -32.51% | -43.90% | -62.33% | -53.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.60% | -32.51% | -43.90% | -62.33% | -53.57% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 78.60% | -32.51% | -43.90% | -62.33% | -53.57% |
| SG&A Expenses | 17.17% | 15.16% | 3.20% | -7.78% | 5.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.24% | -14.48% | 13.16% | 12.11% | -13.06% |
| Operating Income | -25.61% | 11.96% | -26.18% | -34.71% | 8.92% |
| Income Before Tax | -28.45% | 10.52% | -139.35% | 78.20% | 14.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.45% | 10.52% | -139.35% | 78.20% | 14.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.45% | 10.52% | -139.35% | 78.20% | 14.92% |
| EBIT | -25.61% | 11.96% | -26.18% | -34.71% | 8.92% |
| EBITDA | -26.21% | 11.94% | -27.20% | -35.70% | 8.96% |
| EPS Basic | -0.33% | 23.17% | -130.88% | 89.77% | 76.52% |
| Normalized Basic EPS | -1.14% | 25.40% | -121.82% | 91.66% | 77.98% |
| EPS Diluted | -0.33% | 23.17% | -130.88% | 89.77% | 76.52% |
| Normalized Diluted EPS | -1.14% | 25.40% | -121.82% | 91.66% | 77.98% |
| Average Basic Shares Outstanding | 27.99% | 16.46% | 27.44% | 113.06% | 262.40% |
| Average Diluted Shares Outstanding | 27.99% | 16.46% | 27.44% | 113.06% | 262.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |